Introduction
Schizophrenia is a common mental disorder with a devastating disturbance of mind and personality affecting 0.5-1% of the general population at some point in their lives. The aggregation of schizophrenia in families, and the results of many twin and adoption studies support the hypothesis of an inherited risk factor for the disease. As yet, no mutations, or disease predisposing DNA sequence variations, have been identified. Dopamine is a major neurotransmitter involved in the control of motor, affective, cognitive and neuroendocrine function. 1 Abnormal dopaminergic transmission has been suggested (but never clearly shown) to play a central role in the pathogenesis of schizophrenia. 2 A common feature of almost all drugs used to treat schizophrenia is their ability to block dopamine receptors. Furthermore, drugs that elevate levels of circulating dopamine induce psychotic symptoms in schizophrenic patients in remission and in some healthy individuals. 3 Molecular cloning and characterization of dopamine receptor genes 1, [4] [5] [6] [7] [8] has paved the way for genetic investigation into the possible role of mutations, or DNA Correspondence: Z Hawi, Department of Genetics, Trinity College, Dublin 2, Ireland. E-mail:zhhawiȰ.tcd.ie(ZHHAWI) Received 15 October 1997; revised and accepted 2 December 1997 polymorphisms, in the dopamine receptor genes in schizophrenia. The dopamine DRD3 gene is expressed almost exclusively in the limbic system and thus represents an attractive target for genetic analysis. The gene is mapped to chromosome 3q13.3; the coding sequence is 661 bp in length and contains six exons. 9 Association studies of DRD3/MscI polymorphism (Serine-9-Glycine substitution) and schizophrenia have produced interesting but conflicting findings. In a study of Welsh and French schizophrenic patients, significant association was observed between the disease and homozygosity for DRD3 variants 1-1 and 2-2. 10 Extending the sample size, the association was found to be most marked in schizophrenic males, those with family history and in good responders to antipsychotic drugs. 11, 12 In independent samples of patients and controls, Nimgaonkar et al 13, 14 suggested an association with allele 1 and Shaikh et al 15 likewise showed an association with allele 1. In contrast, Kennedy et al 16 showed a higher frequency of allele 2 and genotype 2-2 in their patients and most recently Ebstein et al 17 found the allele 2 and the genotype 2-2 to be significantly associated with the disease in a combined sample of Italian, Ashkenazi and non-Ashkenazi Jews. These studies only partly confirmed the original hypothesis of an excess of homozygosity or found something new altogether. In addition, investigations from Germany, 18, 19 Sweden, 20 France, 21 Italy, 22 Spain, 23 Japan [24] [25] [26] and China [27] [28] [29] failed to detect evidence of either allelic or genotypic association or excess of homozygosity in their schizophrenic samples.
Three studies used family-based association designs, more robust than the case-control method. Williams et al 30 in a combined European sample of 45 probands and their parents found a significant excess of homozygosity in transmitted alleles compared to untransmitted alleles whereas Rothschild et al 31 and Macciardi et al 32 using the transmission disequilibrium test, found no association.
Despite being the most extensively studied marker/locus in schizophrenia, there remains no consensus as to whether or not any form of association exists, or whether the association is confined to a particular patient group, for example, in male patients, schizophrenics with high familial loading, [11] [12] [13] [14] those with an early age of onset 17 or those with a poor response to neuroleptics. 15 To examine some of these issues we have genotyped the DRD3/MscI polymorphism in a sample of 198 Irish familial schizophrenic patients compared to ethnically matched controls. In addition, we have genotyped microsatellite markers flanking the DRD3 gene to test for evidence of genetic linkage with schizophrenia using the full set of 265 multiplex families forming the Irish study of high density schizophrenia families (ISHDSF).
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Material and methods
Samples
Fourteen hundred and eight individuals from 265 multiplex schizophrenic pedigrees forming the Irish High Density Schizophrenia Families (ISHDSF) were included in this study. In addition, 198 affected core phenotype schizophrenics were randomly selected, one from each of 198 families, to make up the cases for the case control study. Details of the families and the diagnostic methods can be found in Kendler et al 33 and Straub et al. 34 In summary, diagnoses were made using the Structured Interview for DSM-III-R (SCID), 35 the structure interview for schizotypy (SIS), 36 hospital records and family history information. All patients satisfied the DSM-III-R criteria for schizophrenia. Two hundred and thirty nine ethnically matched controls were obtained from the Irish blood donor service. These individuals were not screened for psychiatric disorder, but were not on medication at the time of donation.
DNA genotyping
DNA extraction was performed using the standard phenol chloroform method. Primers and amplification conditions of the segment containing the DRD3/MscI polymorphic site and the microsatellite markers are listed in Table 1 . The microsatellite markers are located 1.1 cM proximal (D3S1572) and 1.8 cM distal (D3S1310) to the DRD3 gene. 37 Standard PCR reaction was carried out in 25-l volumes containing 60 ng of genomic DNA, 0.4 M of each primer, 200 M of each dNTP, 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 1.75 mM MgCl 2 , 0.001% gelatin and 1 U of Taq polymerase. For the DRD3/MscI polymorphism an aliquot of 10 l of the PCR product was digested with MscI and the fragments resolved in 2.5% agarose. Depending on the absence or the presence of the polymorphic MscI restriction site, either a fragment of 304 bp (allele 1) or two fragments of 206 and 98 bp (allele 2) are produced. Genotyping of microsatellite markers was achieved by incorporating ␣ 32 p dCTP in the PCR mix and separating the products on 6% denaturing polyacrylamide gels. All genotypes were scored independently by two investigators.
Statistical analysis DRD3/MscI alleles and genotypes in patients and controls were tabulated and the frequencies compared using a chi-square test. Linkage analyses were carried out using four definitions of the disease as follows: categories D1-D2, the core schizophrenic phenotypes including schizophrenia, poor outcome schizoaffective disorders and simple schizophrenia; categories D1-D5, including the above diagnosis and schizophreniaform disorder, delusion disorder, atypical psychosis, good outcome schizoaffective disorder and schizotypal personality disorder; categories D1-D8, including all the above and disorders which significantly aggregate in relatives of schizophrenics; and categories D1-D9, which include all psychiatric disorders such as nonpsychotic affective disorder, anxiety disorder and other non-schizophrenia spectrum personality disorders (for further details see Straub et al 34 ) . For each definition of the disease, analyses were carried out with four genetic models as described in Gill et al 38 39 ) were calculated for all analyses.
Results
Genotypes in both patient and control samples showed no significant differences from those expected according to Hardy-Weinberg equilibrium. A small increase in the frequency of the genotype 1-1 (patients 41.9% vs controls 39.1%) and 2-2 (patients 14.1% vs controls 10.2%) was observed, however none of these differences was statistically significant (Table 2 ). This was also accompanied by a similar non-significant decrease in the frequency of the genotype 1-2 in the patient population (patients 45.0% vs controls 50.6%). With respect to zygosity, there is a slight increase in the number of individuals homozygous for 1-1 and 2-2 in the patient population compared to the controls but this was not significant (patients 56.0% vs controls 49.4%, Chi-square = 1.9, d.f. = 1, P = 0.16). Analysis of data in terms of alleles rather than genotypes also failed to show significant differences in the distribution of the DRD3 alleles in patients and controls. When patients and controls were divided according to sex (Table 3) , there were no significant differences in either allele or genotype frequencies between patients and controls. The results of lod score analyses for the diagnostic and genetic models are presented in Tables 4 and 5 . Substantial negative lod scores were obtained for all models. In addition, neither the A-test nor the C-test showed any evidence to support the hypothesis of linkage in a subset of the families.
Discussion
The present study does not support the original hypothesis of an excess of homozygosity or any of the derived hypotheses including allelic or genotypic association. The sample is the largest studied to date and has a power greater than 95% to detect an effect size of the magnitude reported by Crocq et al. 10 Furthermore, the sample is ethnically homogeneous and all patients are probands from multiply affected pedigrees displaying the core schizophrenia phenotype. In addition, the ISHDSF has a substantial power to detect susceptibility loci for schizophrenia even if it was present in as few as 20% of the families, 33 however, no evidence of linkage was detected with microsatellite markers 1.1 cM proximal and 1.8 cM distal to the DRD3 locus. 37 To our knowledge, there are 22 published reports of genetic association studies of the Serine-9-Glycine substitution in schizophrenia involving 2430 patients and 2139 controls. In addition there are a further three studies using robust transmission disequilibrium designs. The frequency of the common allele (allele 1) is reasonably stable across diverse populations apart from African-Americans. Leaving aside the AfricanAmerican population reported by Nimgaonkar et al 14 where the frequency was 0.29, allele 1 frequency in control populations varied from 0.55 in a Scottish sample 15 to 0.78 in a Japanese sample. 26 In total, eight case- control studies had positive findings, but with little or no consistency as to the associated allele or genotype, and therefore these require examination in more detail. The original study (Crocq et al 10 ) based on Welsh and French samples demonstrated significant association in each sample between homozygosity at DRD3/MscI and schizophrenia, however, the genotype frequencies in the French controls were abnormal in that they showed an excess of heterozygosity.
Further studies from the same group expanded the original Welsh sample and demonstrated a stronger effect for male sex, 11 positive family history and good responders to neuroleptic treatment. 12 Yet except for males in the study reported by Asherson et al (Chi-square = 4.62, d.f. = 1, P = 0.03), the new samples failed to confirm the original hypothesis. They suggested that as the effect appeared to be stronger in familial cases, the differences in this respect between samples might account for the absence of a significant effect in the second sample. However, sub-dividing the samples by clinical parameters introduced more tests, and this has generally not been taken into account in subsequent studies. In addition, the sample used in the present (ISHDSF) study is strongly familial and therefore should have easily detected the effect. As with the Welsh sample, the French sample was also subsequently enlarged, 9 but the strength of the original association reported in Crocq et al 10 (Chi-square = 6.96, d.f. = 1, P = 0.008) was weakened (Chi-square = 5.3, d.f. = 1, P = 0.02).
The next positive findings were reported by Nimgaonkar et al. 13 They failed to confirm the homozygosity hypothesis, but in a small sub-sample (n = 10) of familial cases, they found allele 1 and genotype 1-1 to be significantly more frequent than in 48 controls. Here, the hypothesis has shifted and as above, more tests were introduced. Later, the same group enlarged the sample showing the same association in family history-positive patients (n = 13) compared to controls, but no associations with a larger sample of family history-negative patients.
14 They also reported a new sample of African-American origin, which, if family history-positive patients are selected (n = 20), showed an excess of the 1-1 genotype, compared to 63 adult controls. Finally, when familial and non-familial cases were pooled together and compared to their respective total control samples, the only significant association was with genotype 1-1, in the Africian-American sample.
Shaikh et al 15 examined a sample of patients from throughout the UK with two control samples, one from London and one from Scotland. They failed to confirm the homozygosity association but found a significant excess of allele 1 in the total sample of patients -a further new hypothesis requiring to be tested. In addition they divided their sample into responders and non-responders to clozapine (all patients were taking clozapine at the time of study). They found a weakly significant excess of genotype 1-1 in non-responders. It should be noted that in this study there was no difference in genotype distribution as a whole between the two groups and therefore three tests were performed and the results presented without correction. Moreover, the excess of 1-1 in non-responders is in contrast to the findings of Mant et al 12 who found a higher 1-1 frequency in those with a good response to neuroleptic medication.
A further twist has also been added to the story by two groups who report significant associations with allele 2 and genotype 2-2 in a Northern American population 16 and in a combined sample of Italian, Ashkenazi and non-Ashkenazi Jews. 17 Careful consideration of the Ebstein et al 17 study demonstrated the absence of an association with homozygosity in the combined sample and in each of the groups separately.
In addition, the significant association of the genotype 2-2 is restricted to the non-Ashkenazi Jews and not detected in the Italian and Ashkenazi Jews. Furthermore, the size of the studied schizophrenic (nonAshkenazi) and control populations was small (46 and 27 respectively). Finally, the non-Ashkenazi Jews are not a homogeneous population and ideally therefore should be subclassified into Sephardic and Oriental subgroups and the Oriental subgroup by region of origin (North Africans and Asians), as described by the authors. Kennedy et al 16 showed higher allele 2 and genotype 2-2 frequencies in North American patients compared to unmatched controls. When cases and controls were subsequently matched for sex, ethnic background and age the apparent association disappeared.
In the three studies which used transmission disequilibrium tests, one found evidence for an association, and two did not. Williams et al 30 reported a study of 45 patients and their parents derived from 11 centres across Europe. A significant excess of homozygosity was observed in schizophrenia compared with 'non-transmitted parental alleles' (Chi-square 4.68, d.f. = 1, P = 0.02, one-tailed). No allelic association was observed but a non-significant trend towards association with the 1-1 genotype was detected. However, a similarly designed study reported by Macciardi et al 32 found no difference in transmitted compared to nontransmitted alleles, and a test for transmission disequilibrium in 45 multiplex families showed no evidence for an association due to linkage disequilibrium. 31 It is almost impossible to completely refute the assertion that allelic or genotypic variants of the DRD3/MscI polymorphism (or DNA variation in linkage disequilibrium with them) are associated with schizophrenia, and that the many negative studies, including the present study which reports on the largest sample studied to date, report false negative findings. If the effect of homozygosity is small, then the pattern of apparent replication and non-replication is exactly what one would expect. A meta-analysis may reveal an effect when data from all studies are considered. Alternatively it could be argued that the association is only present in some populations, despite the lack of any 'ethnic' pattern to the results. However, the most parsimonious explanation is that there is no genotypic or allelic association and that the significant results to date represent false positive findings. We propose that none of the case-control studies are convincing. The study by Williams et al 30 is only published in abstract form and provides insufficient detail to scrutinise closely. In conclusion, the result of the present study and many others (those that failed to identify association or linkage with this marker or linkage with closely mapped markers) do not support a role for the DRD3/MscI polymorphism in the pathogenesis of schizophrenia.
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